STAY FOREVER YOUNG
We revolutionize
DNA repair
AGING: A DISEASE CAUSED BY DNA DAMAGE
Every day, millions of DNA lesions accumulate in our cells, gradually degrading biological performance. DNA damage is the most fundamental driver of aging and age-related disorders.
STOPPING DNA DAMAGE: THE SOLUTION FOR STAYING FOREVER YOUNG
Reducing DNA damage and enhancing its repair are the most direct ways to significantly slow aging, extend healthy lifespan, and ultimately keep you younger for much longer.
XTRALIFE HAS THE KEYS TO BECOME THE GLOBAL LEADER IN LONGEVITY
XtraLife is developing next-generation DNA-repair–enhancing solutions powered by artificial intelligence, applied beyond cutting-edge knowledge in genome stability.
XtraLife
Our expertise
XtraLife brings together a team with top-level expertise in longevity and DNA repair, built over decades of scientific work.
With advanced discovery technologies, we are uniquely positioned to develop nature-derived nutraceuticals that target genomic damage and slow aging at its source, setting the foundation to become a leader in this emerging space.
AI-based technology
Our collaboration with CORTEX DISCOVERY GmbH is at the core of our solution.
Cortex uses an AI foundation model trained on a proprietary dataset of millions of molecules and nearly a billion data points to achieve lab-grade prediction accuracy.Independent studies have validated that its computationally identified molecules can produce real biological effects.
Laboratories &
testing pipelines
AI-selected compounds will be validated in vitro by independent laboratories.
HUMAN-CELL TESTING
AI-predicted candidates are first validated in human cell models to assess DNA repair, oxidative stress resilience, mitochondrial health, and aging biomarkers.
CONSUMER-DERIVED CELL TESTING
Promising compounds will then be tested on cells derived from real consumers, offering key insight into biological response before final formulation.
Production and commercialization
(End 2026)
By late 2026, XtraLife will launch GMP-grade manufacturing through selected partner manufacturing labs, enabling large-scale production of its novel DNA-repair nutraceuticals while ensuring purity, consistency, and reliable global supply.
Our board
Dr Ivan DE WEBER
Dr. Ivan de Weber is a scientist and entrepreneur with a lifelong focus on longevity. His journey from cell biology to pharmaceutical bioinformatics was shaped by the explosion of biomedical data, where he recognized the transformative potential of modern machine learning in drug discovery. As Co-Founder and CEO of Cortex Discovery GmbH, he leads the strategic collaboration with XtraLife.
Dr Axel SCHUMACHER
Dr. Axel Schumacher is an epigenetics and longevity expert with over twenty years of experience at the intersection of biology, data, and aging science. He has founded and led multiple biotech companies across Europe, North America, and Asia, advancing innovations in genomics, precision medicine, AI-driven diagnostics, and aging biomarkers. Renowned for pioneering contributions such as the first descriptions of epigenetic clocks, epigenetic drift in Alzheimer’s, epigenetic SNPs, and single-cell epigenomics, he brings deep expertise in genomic aging and translational longevity research to XtraLife.
Dr. Marie-Hélène BLANCHET-ZUMOFEN
Dr. Marie-Hélène Blanchet-Zumofen offers over a decade of expertise spanning clinical development and commercial strategy in the pharmaceutical industry. After serving as a clinical scientist at Actelion, she moved to Roche, where she is now Global HTA Evidence Lead and has held several strategic positions in market evaluation, sales strategy, and evidence planning. She provides XtraLife with strong regulatory, clinical, and commercial guidance.
